Current Report Filing (8-k)
September 13 2021 - 8:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 13, 2021
ENOCHIAN BIOSCIENCES INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-54478
|
|
45-2559340
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
2080
Century City East
Suite 906
Los Angeles, CA 90067
(Address of principal executive offices)
(Zip Code)
|
+1 (305) 918-1980
(Registrant's telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.0001 per share
|
|
ENOB
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
Enochian Biosciences
Inc., a Delaware corporation (the "Company"), today has made available an Investor Presentation at the H.C. Wainwright
23rd Annual Global Investment Conference, during which our Chief Executive Officer, Dr. Mark Dybul, participated in a webcast.
The Investor Presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
The information
included in this Item 7.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
The Company undertakes
no duty or obligation to update or revise information included in this Report or the Exhibit.
Item 9.01
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ENOCHIAN BIOSCIENCES,
INC.
|
|
|
|
By:
|
/s/
Mark Dybul
|
|
|
Name:
Mark Dybul
Title: Chief Executive Officer
|
Date: September 13, 2021
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2024 to May 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From May 2023 to May 2024